Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01478594 · ClinicalTrials.gov registry record · Phase 2
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2 study, sponsored by AVEO Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 265
- Enrollment target
NCT01478594 is a Phase 2 study that has completed, run by AVEO Pharmaceuticals. The registered enrollment target is 265 participants.
The verdict
NCT01478594, a Phase 2 study, has completed, sponsored by AVEO Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 265 participants
- Enrollment target
Study Summary
The objective of this study is to compare the progression free survival (PFS), overall survival (OS), objective response rate (ORR), time to treatment failure (TTF), duration of response (DoR), quality of life, safety and tolerability of tivozanib in combination with mFOLFOX6 and bevacizumab in combination with mFOLFOX6.
Interventions
- DRUG Bevacizumab
- DRUG Tivozanib
- DRUG mFOLFOX6
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2011-12 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01478594
The ClinicalTrials.gov registry entry for NCT01478594 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 265 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AVEO Pharmaceuticals, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT01478594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01478594 about?
NCT01478594 is a clinical study titled "A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy". The objective of this study is to compare the progression free survival (PFS), overall survival (OS), objective response rate (ORR), time to treatment failure (TTF), duration of response (DoR), quality of life, safety and tolerability of tivozanib in combination with mFOLFOX6 and bevacizumab in comb...
What is the current status of trial NCT01478594?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 265 participants. The study started on 2011-12. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01478594?
The interventions under investigation include: Bevacizumab (DRUG), Tivozanib (DRUG), mFOLFOX6 (DRUG).
Who is sponsoring clinical trial NCT01478594?
This trial is sponsored by AVEO Pharmaceuticals, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.